

# Pathogenic Characteristics Of Pandemic Influenza Viruses

#### Ruben Donis, PhD

Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority (BARDA) Assistant Secretary for Preparedness and Response (ASPR) Department of Health and Human Services, USA

> 2018 WORLD INFLUENZA CONFERENCE Beijing Conference Center, September 8, 2018

## **ASPR's Mission**

Save Lives and Protect Americans from 21st Century **Health Security** Threats





# **The BARDA Model**

BARDA develops and makes available medical countermeasures (MCMs) by forming unique public-private partnerships with industry partners






## **BARDA Pandemic Influenza Preparedness**



Early Detection  $\rightarrow$  Early Response  $\rightarrow$  Saving Lives






## Lessons Learned From 2009 H1N1 Pandemic





ΓΙΜΕ

BIRD FLU







# **IRAT Informs Pre-pandemic Preparedness**

#### Attributes of the virus

7

- Receptor Binding Properties
- Transmission in Animal Models
- Genomic Variation
- Antiviral Susceptibility

#### Attributes of the population

- Population Immunity
- Disease Severity

**Critical Elements** 

Antigenic Similarity to Vaccines

Virologic

Surveillance


#### **Ecology and epidemiology**

- Human Infections
- Infections in Animals
- Global Distribution

Disease

Surveillance

4SPR




https://www.cdc.gov/flu/pandemic-resources/monitoring/irat-virus-summaries.htm

## Severity and Transmissibility of 2009 H1N1 Pandemic

### Low to moderately severity


- 2009 H1N1
  - "Recycled" HA from 1918
  - Eurasian avian M and NA
  - Classical and Eurasian swine genes
- Minimal adaptive changes were needed
  - Most genes were of human origin maintained in swine






## **2009 H1N1: Transmissibility and Population Immunity**

Laboratory-confirmed Influenza



#### Serum Antibody to A(H1N1)pdm09



Median age: 12-15 years

Hancok K et al. NEJM (2009) 361(20):1945-52

Jacobs JH, et al. (2012) PLOS ONE 7(8): e42328. CDC. MMWR 2009;58(33):913–918.




## Severity & Transmissibility of '57 H2N2 and '68 H3N2

### **High severety**

- 1957 H2N2 subtype
  - Novel H3 HA + N2 NA
  - Avian PB1

### **Moderate severety**

- 1968 H3N2 subtype
  - Novel H3 HA
  - New avian PB1
  - Immunity to N2 dampened severity?



\* Reed, C. et al. Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics. Emerg Infect Dis 19, 85-91 (2013).




### **Animal-origin HA/NA Adaptation to Human Host**

### **HA** adaptation

- Recognize 2-6 sialic acidcontaining receptors in the human upper airway tract
- Optimal acidic pH trigger for fusion (stability)
- Appropriate susceptibility to specific proteases as activators of fusion function

### NA adaptation

 Altered enzymatic activity for functional balance with HA






# Severity and Transmissibility of 1918 H1N1

### Very high severity

- Direct avian to human?
- Avian to swine to human?
- HA + NA + Internal genes
- Tumpey et al. H1N1
- Herfst et al. H5N1
- Imai et al. H5N1/H1N1

Tumpey, et al. (2005) Science 310; p77-80





\* Reed, C. et al. Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics. Emerg Infect Dis 19, 85-91 (2013).



## The Reconstruction of 1918 H1N1

- 1918 H1N1 virus recued by RG
  - Landmark achievement
    - ✓ Tumpey et al 2005
    - ✓ Taubenberger et al. 2001
  - Experimental infections
  - In vitro and in vivo
  - Structural biology
  - Omics






#### Darisuren Anhlan et al. RNA 2011;17:64-73

Guan et al. Protein Cell. 2010 1(1):9-13.



## 1918 H1N1 Pathogenicity: Viral Replication & Transmission Machinery In Animal Models




	Protease cleavage activation		
HA	Sialoside receptor binding specificity		
	Membrane fusion/pH optima		
NA	NA Glycan cleavage catalysis optima		
M2	M2 Ion channel activity, uncoating, folding		
NS2	NS2 Nucleocytoplasmic traffic		
PB1	Replicase and transcriptase, fidelity		
PB2	RNA Cap-binding		
PA	RNA Cap endonuclease		
NP & M	Genome structure and virion assembly		
NS1	Host response modulation		



# **Pathology:1918 and Subsequent Pandemics**

- 1918 pathologic findings are similar to those of autopsies from the 1957 and 2009 pandemics
- No unique pathological mechanisms
  - similar cell tropism
  - similar virus distribution
- Co-morbidities; obesity, cardio



Gill, J. R. et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med **134**, **235-243 (2010)**.




# **1918 H1N1: Bacterial Superinfection**


- Bacterial superinfections in fatal pandemic flu
  - ~90% in 1918
  - ~75% in 1957
  - ~55% in 2009
  - Streptococcus pneumoniae
  - Haemophilus influenza
  - Mycoplasma pneumonia
  - Staphylococcus aureus
- A future 1918-like pandemic would be much less severe due to antibiotic therapy
- The search for answers on 1918 virulence continues!

Kash, J. C. & Taubenberger, J. K. *Am J Pathol 185, 1528-1536,* Gill, J. R. *et al. Arch Pathol Lab Med 134, 235-243 (2010).* 





# H7N9 IRAT Pandemic Emergence Risk: 6.5



Jernigan, D. Ann Rev Med 66, 2015 pp 361-371



# H9N2 Pandemic Emergence Risk: 5.6

		Virus	Emergence Score	Impact Score
		H7N9 [A/Hong Kong/125/2017]	6.5	7.5
	Γ	H9N2 G1 lineage [A/Bangladesh/0994/2011]	5.6	5.4
		H5N1 Clade 1 [A/Vietnam/1203/2004]	5.2	6.6

#### **Similarities**

- Human infections: sporadic
- Receptor: significant 2-6 binding
- Internal genes: shared ancestry
- Evolution: multiple reassortments and antigenic drift

Wu ZQ, Int. J. Environ. Res. Public Health 2017, 14, 263; Stephenson I., Lancet. 2003 Dec 13;362(9400):1959-66.

#### Differences

- Severity in humans: H7N9 CFR: ~30%
- Immunity in humans: H9N2 > H7N9
- Age distribution: H9N2 median =13 years, H7N9 median = 61 years
- Geographic distribution: H7N9 1 country, H9N2 widely in 2 continents
- H9N2 frequently detected in swine




### **Predictable Unpredictability of Pandemic Influenza**

- Global Challenges
  - Unknown pathogenic characteristics of the next pandemic virus
  - Faster spread than ever
  - Greater potential for societal disruption



- Global Opportunities
  - Better global pandemic surveillance
  - Faster communications, international collaboration
  - Improved pandemic response capabilities
  - Better and faster diagnostics, masks, vaccines and drugs





# **Thank You!**

